Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

1:00pm - 2:00pm 60 mins
Main agenda
Design Principles for Bispecific IgGs - Opportunities and Pitfalls of Artificial Disulfide Bonds
  • Itai Benhar, Ph.D. - Professor, Molecular Microbiology and Biotechnology, Tel-Aviv University

1:00-2:00pm ET

We present a solution for correct pairing of heavy and light chains of bispecific IgGs; an engineered disulfide bond between the antibodies’ variable domains that asymmetrically replaces the natural disulfide bond between CH1 and CL. Bispecific IgGs where the artificial disulfide bond is placed in the CH1-CL interface are also discussed. A novel approach for precise evaluation of correct chain pairing by LC-MC-MS combined with chemical crosslinking is presented. Examples will be provided for some of these bsAbs and future directions of the study will be discussed.


3:00pm - 4:00pm 60 mins
Main agenda
Wnt Pathway Inhibitory Antibody for Fibro-Inflammatory Disease
  • Andrew Mendelsohn, Ph.D. - Director, Molecular Biology, Panorama Research, Inc.

3:00-4:00pm ET

The Wnt pathway plays a key role in tissue repair, but abnormal Wnt signaling is a hallmark of fibrotic and inflammatory diseases. Targeting canonical Wnt signaling is a potential rational way to treat a large set of pathologies. We are developing a therapeutic antibody that inhibits Wnt signaling co-receptor LRP6. This antibody has self-limited activity which may allow the ubiquitous Wnt pathway to be safely modulated.